帕尼单抗治疗结肠癌：生物标志物困境

Panitumumab in the treatment of colon cancer: A biomarker dilemma.

作者信息

Scott A, Messersmith W A, Jimeno A, Davies S L

机构信息

University of Colorado Denver, Aurora, Colorado, USA.

出版信息

Drugs Today (Barc). 2014 Oct;50(10):679-90. doi: 10.1358/dot.2014.50.10.2221787.

DOI:10.1358/dot.2014.50.10.2221787

PMID:25374966

Abstract

Panitumumab is a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR) approved for use in colorectal cancer (CRC). Critical information regarding biomarkers in CRC has been discovered through the investigation of panitumumab treatment. The discovery of anti-EGFR resistance in the setting of Kirsten rat sarcoma viral oncogene (KRAS) and more recently, neuroblastoma RAS viral oncogene (NRAS) mutations in CRC has changed the focus of therapy for metastatic disease to one based on the molecular characteristics of the tumor. This review will give a brief background on panitumumab and its current uses in CRC.

摘要

帕尼单抗是一种完全人源化单克隆抗体，靶向表皮生长因子受体（EGFR），已被批准用于治疗结直肠癌（CRC）。通过对帕尼单抗治疗的研究，已发现了有关CRC生物标志物的关键信息。在结直肠癌中， Kirsten大鼠肉瘤病毒癌基因（KRAS）以及最近发现的神经母细胞瘤RAS病毒癌基因（NRAS）突变情况下抗EGFR耐药性的发现，已将转移性疾病的治疗重点转变为基于肿瘤分子特征的治疗。本综述将简要介绍帕尼单抗及其在结直肠癌中的当前应用背景。